These data suggest that multiple immune checkpoint pathways, not only the PD-1/PD-L1 axis, cause immune tolerance and escape in patients with high NOTCH3 expression and result in poor outcomes in GC patients. This evidence concerns the gene NOTCH3 and gastric cancer.